Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.82 |
| ▸ | KDR | P35968 | 8/20 | 0.82 |
| ▸ | RET | P07949 | 5/20 | 0.82 |
| ▸ | LCK | P06239 | 3/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.67 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.62 |
| ▸ | FLT1 | P17948 | 2/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | STK10 | O94804 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257431 | 0.90 | EGFR (1.00) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL29515328 | 0.90 | EGFR (1.00) | EGFRKDRRETLCKRIPK2 | |
| Hydrochloric Acid SCHEMBL5475737 | 0.89 | EGFR (1.00) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL1387182 | 0.88 | EGFR (0.94) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL13604745 | 0.86 | EGFR (0.82) | EGFRKDRRETLCKRIPK2 | |
| Hydrochloric Acid SCHEMBL8807895 | 0.86 | EGFR (0.95) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL20050502 | 0.85 | EGFR (0.80) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL20050182 | 0.85 | EGFR (0.80) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL21442463 | 0.85 | EGFR (0.84) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL13604741 | 0.83 | EGFR (0.85) | EGFRKDRRETLCKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-9040548-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2014-05-01 | — | — | US | disclosed |
| US-8642608-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2014-02-04 | — | — | US | disclosed |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB | 2007-11-15 | — | — | US | disclosed |
| US-7173038-B1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | EGFR 199/4885KDR 3/4885RET 503/4885 |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | FLT1, FLT4, KDR | EGFR 183/4885KDR 3/4885RET 526/4885 |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | EGFR 183/4885KDR 3/4885RET 526/4885 |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 181/4885KDR 3/4885RET 446/4885 |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | EGFR 120/4885KDR 3/4885RET 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.